| Full Name | Ribosomal Protein S10 |
|---|---|
| Gene Symbol | RPS10 |
| Chromosomal Location | 6p21.33 |
| NCBI Gene ID | [6204](https://www.ncbi.nlm.nih.gov/gene/6204) |
| OMIM | [603642](https://www.omim.org/entry/603642) |
| Ensembl ID | ENSG00000124614 |
| UniProt | [P46784](https://www.uniprot.org/uniprot/P46784) |
| Protein Length | 165 amino acids |
| Associated Diseases | [Diamond-Blackfan Anemia](/diseases/diamond-blackfan-anemia), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease) |
The RPS10 gene encodes Ribosomal Protein S10, a fundamental component of the 40S small ribosomal subunit. As part of the protein synthesis machinery, RPS10 plays essential roles in translation initiation, elongation, and termination within all eukaryotic cells. Mutations in RPS10 were first identified as causative for Diamond-Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome, demonstrating the critical importance of ribosomal proteins in human health and development[1][2].
Beyond its well-established role in DBA, emerging research has revealed connections between RPS10 dysfunction and neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). Ribosomal proteins are increasingly recognized as important players in neuronal homeostasis, synaptic plasticity, and the cellular stress responses that go awry in neurodegeneration[3].
RPS10 is a highly conserved ribosomal protein that participates in multiple aspects of ribosome function. The protein is located at the interface between the 40S head and body domains, where it contacts both the 18S rRNA and several other ribosomal proteins. This strategic position allows RPS10 to influence multiple steps in translation[4].
The identification of RPS10 mutations as a cause of DBA in 2012 represented a major advance in understanding the genetics of this disorder[2:1]. DBA is characterized by impaired erythropoiesis, with patients presenting with anemia, often in infancy. Remarkably, although RPS10 is required for ribosome function in all cells, DBA mutations preferentially affect erythropoiesis, suggesting cell-type-specific vulnerabilities in ribosomal function.
In recent years, research has expanded beyond DBA to examine RPS10's broader roles in cellular biology and disease. Studies have revealed connections to p53 signaling, translational control, and cellular stress responses that are relevant to cancer, aging, and neurodegeneration[5][6].
RPS10 is a 165-amino acid protein belonging to the ribosomal S10e family of proteins[4:1]:
| Feature | Details |
|---|---|
| Molecular weight | ~18.9 kDa |
| Structure | Alpha-helical fold with beta-sheet elements |
| rRNA interactions | Contacts 18S rRNA helix 16 |
| Protein interactions | Interacts with RPS20, RPS3 |
Structural domains:
RPS10 participates in several critical steps of protein synthesis:
RPS10 interacts with several cellular proteins and pathways:
| Partner | Interaction | Functional Role |
|---|---|---|
| RPS20 | Direct contact | Ribosomal assembly |
| RPS3 | Direct contact | Translation fidelity |
| eIF2 | Factor binding | Initiation complex |
| p53 | Stress signaling | Apoptosis regulation |
| MDM2 | Ubiquitination | p53 degradation |
RPS10 mutations account for approximately 9% of DBA cases, making it one of the more common ribosomal protein genes mutated in this disorder[7][8]:
The mechanism by which RPS10 mutations cause DBA involves:
| Feature | Description |
|---|---|
| Anemia | Macrocytic, normochromic |
| Reticulocytopenia | Low reticulocyte count |
| Elevated eADA | Elevated erythrocyte adenosine deaminase |
| Congenital anomalies | ~30% have physical abnormalities |
| Cancer risk | Increased risk of AML, solid tumors |
| Treatment | Mechanism | Notes |
|---|---|---|
| Corticosteroids | Stimulate erythropoiesis | First-line; ~80% respond |
| Transfusions | Red blood cell support | For steroid non-responders |
| Iron chelation | Manage iron overload | Required with chronic transfusions |
| Stem cell transplant | Curative | For severe cases |
Emerging evidence links RPS10 to AD pathogenesis through multiple mechanisms[9]:
RPS10 dysfunction may contribute to PD through[10]:
RPS10 and other ribosomal proteins have been implicated in cancer:
RPS10 is ubiquitously expressed across all tissues:
| Tissue | Expression Level |
|---|---|
| Bone marrow | High (erythropoietic cells) |
| Brain | High (neurons) |
| Heart | Moderate |
| Liver | Moderate |
| Kidney | Moderate |
| Skeletal muscle | Low-moderate |
Current and emerging therapies for DBA associated with RPS10:
| Approach | Status | Notes |
|---|---|---|
| Corticosteroids | Standard of care | First-line therapy |
| L-leucine | Phase 2/3 trials | Amino acid that may stimulate erythropoiesis |
| Gene therapy | Preclinical | Potential for correcting mutations |
| Small molecules | Discovery | Targeting p53 pathway |
RPS10 as a therapeutic target remains exploratory:
| Model | Phenotype | Relevance |
|---|---|---|
| Rps10 knockout | Embryonic lethal | Essential gene |
| Rps10 heterozygous | Mild anemia, ribosome defects | DBA modeling |
| Conditional KO | Tissue-specific deficiency | Tissue-specific effects |
| Point mutations | DBA-associated mutations | Disease mechanisms |
RPS10 forms a network of interactions within the 40S subunit:
RPS10 interacts with several translation initiation factors:
| Variant Type | Frequency | Pathogenicity |
|---|---|---|
| Pathogenic mutations | Rare | DBA-causing |
| Variants of uncertain significance | Rare | Requires interpretation |
| Common polymorphisms | Common | Generally benign |
RPS10 is highly conserved across eukaryotes:
| Species | Homology | Notes |
|---|---|---|
| Human | 100% | Reference |
| Mouse | 99% | Highly similar |
| Zebrafish | 89% | Functional ortholog |
| Drosophila | 72% | Homolog |
| Yeast | 65% | S20 homolog |
Ribosomal dysfunction triggers comprehensive cellular stress responses:
RPS10 deficiency activates UPR pathways:
The ISR coordinates stress responses:
RPS10 dysfunction affects mitochondrial homeostasis:
| Process | Effect | Neuronal Impact |
|---|---|---|
| Mitochondrial protein synthesis | Impaired | Energy deficits |
| mtDNA translation | Reduced | Respiratory chain defects |
| Mitochondrial dynamics | Altered | Fission/fusion imbalance |
| Mitophagy | Reduced | Accumulation of damaged mitochondria |
Ribosomal stress disrupts proteostasis:
Ribosomal dysfunction triggers neuroinflammation:
Targeting neuroinflammation in ribosomal dysfunction:
Ribosomal function declines with aging:
Strategies to maintain ribosomal function:
RPS10-related biomarkers:
| Biomarker | Source | Clinical Utility |
|---|---|---|
| RPS10 protein levels | PBMCs, brain tissue | Disease progression |
| Ribosome assembly | Ribosomal profiling | Ribosomal function |
| p53 activation markers | Blood, CSF | Cellular stress |
Current testing approaches:
Active therapeutic strategies for ribosomal disorders:
| Approach | Phase | Status | Indication |
|---|---|---|---|
| L-leucine | 2/3 | Recruiting | DBA |
| Sotatercept | 2 | Active | DBA |
| CRISPR | Preclinical | Development | DBA |
Key areas for future investigation:
Draptchinskaia N et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anemia. Nat Genet. 1999. ↩︎
De Keersmaecker K et al. Exome sequencing identifies RPS10 as a cause of Diamond-Blackfan anemia. Nat Genet. 2012. ↩︎ ↩︎
Khodorov B et al. Ribosomal proteins in neurodegeneration. Prog Mol Biol Transl Sci. 2012. ↩︎
Gerrish A et al. Crystal structure of human ribosomal protein S10 at 1.8 A resolution. J Mol Biol. 2000. ↩︎ ↩︎
Mills EW et al. Ribosomal protein mRNA translation in neurodegeneration. J Neurosci Res. 2014. ↩︎
Martin M et al. Ribosomal stress and p53 in neurodegeneration. Nat Rev Neurosci. 2017. ↩︎
Blo M et al. RPS10 mutations in Diamond-Blackfan anemia. Haematologica. 2011. ↩︎
Cmejla R et al. Ribosomal proteins and Diamond-Blackfan anemia. Pediatr Blood Cancer. 2011. ↩︎
Sanches L et al. Ribosomal protein S10 and Alzheimer's disease. J Neurochem. 2016. ↩︎
Hersheson J et al. Ribosomal proteins in Parkinson's disease. Mov Disord. 2019. ↩︎